ARMATA PHARMACEUTICALS, INC. Net Income (Loss) Available to Common Stockholders, Basic
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Net Income (Loss) Available to Common Stockholders, Basic of -$173.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-03-25
- ARMATA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-06-30 was $8.99M.
- ARMATA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2023-06-30 was -$3.55M.
- ARMATA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2018-03-31 was -$3.13M.
- ARMATA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2017-12-31 was -$2.35M.
- ARMATA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was -$173.80M.
- ARMATA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was -$18.92M.
- ARMATA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$69.05M.
- ARMATA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2019 was -$19.48M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | -$173.80M 10-K · filed 2026-03-25 | |||||||
| 2024-12-31 | -$18.92M 10-K · filed 2026-03-25 | |||||||
| 2024-06-30 | $8.99M 10-Q · filed 2024-08-13 | -$16.04M 10-Q · filed 2024-08-13 | ||||||
| 2023-12-31 | -$69.05M 10-K · filed 2025-03-21 | |||||||
| 2023-06-30 | -$3.55M 10-Q · filed 2024-08-13 | -$18.04M 10-Q · filed 2024-08-13 | ||||||
| 2019-12-31 | -$19.48M 10-K · filed 2020-03-19 | |||||||
| 2018-12-31 | -$16.70M 10-K · filed 2020-03-19 | |||||||
| 2018-03-31 | -$3.13M 10-Q · filed 2018-05-15 | -$5.49M derived: sum of 2 quarters · filed 2018-05-15 | -$6.26M derived: sum of 3 quarters · filed 2018-05-15 | -$12.73M derived: sum of 4 quarters · filed 2018-05-15 | ||||
| 2017-12-31 | -$2.35M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$3.13M derived: sum of 2 quarters · filed 2018-03-14 | -$9.59M derived: sum of 3 quarters · filed 2018-03-14 | -$12.84M 10-K · filed 2018-03-14 | ||||
| 2017-09-30 | -$779.00K 10-Q · filed 2017-11-14 | -$7.24M derived: sum of 2 quarters · filed 2017-11-14 | -$10.49M 10-Q · filed 2017-11-14 | -$19.99M derived: sum of 4 quarters · filed 2018-05-15 | ||||
| 2017-06-30 | -$6.46M 10-Q · filed 2017-08-14 | -$9.71M 10-Q · filed 2017-08-14 | -$19.21M derived: sum of 3 quarters · filed 2018-05-15 | -$22.80M derived: sum of 4 quarters · filed 2018-05-15 | ||||
| 2017-03-31 | -$3.25M 10-Q · filed 2018-05-15 | -$12.75M derived: sum of 2 quarters · filed 2018-05-15 | -$16.34M derived: sum of 3 quarters · filed 2018-05-15 | -$22.68M derived: sum of 4 quarters · filed 2018-05-15 | ||||
| 2016-12-31 | -$9.50M 10-K · filed 2017-03-27 | -$13.09M derived: sum of 2 quarters · filed 2017-11-14 | -$19.44M derived: sum of 3 quarters · filed 2017-11-14 | -$24.28M 10-K · filed 2018-03-14 | ||||
| 2016-09-30 | -$3.59M 10-Q · filed 2017-11-14 | -$9.94M derived: sum of 2 quarters · filed 2017-11-14 | -$14.78M 10-Q · filed 2017-11-14 | -$17.96M derived: sum of 4 quarters · filed 2017-11-14 | ||||
| 2016-06-30 | -$6.35M 10-Q · filed 2017-08-14 | -$11.19M 10-Q · filed 2017-08-14 | -$14.37M derived: sum of 3 quarters · filed 2017-08-14 | -$16.09M derived: sum of 4 quarters · filed 2017-08-14 | ||||
| 2016-03-31 | -$4.84M 10-Q · filed 2017-05-15 | -$8.02M derived: sum of 2 quarters · filed 2017-05-15 | -$9.74M derived: sum of 3 quarters · filed 2017-05-15 | -$800.00K derived: sum of 4 quarters · filed 2017-05-15 | ||||
| 2015-12-31 | -$3.18M 10-K · filed 2017-03-27 | -$4.90M derived: sum of 2 quarters · filed 2017-03-27 | $4.04M derived: sum of 3 quarters · filed 2017-03-27 | -$10.79M 10-K · filed 2017-03-27 | ||||
| 2015-09-30 | -$1.72M 10-K · filed 2017-03-27 | $7.22M derived: sum of 2 quarters · filed 2017-03-27 | -$7.61M 10-Q · filed 2016-11-10 | -$8.61M derived: sum of 4 quarters · filed 2017-03-27 | ||||
| 2015-06-30 | $8.94M 10-K · filed 2017-03-27 | -$5.89M 10-Q · filed 2016-08-15 | -$6.88M derived: sum of 3 quarters · filed 2017-03-27 | $7.61M derived: sum of 4 quarters · filed 2017-03-27 | ||||
| 2015-03-31 | -$14.83M 10-K · filed 2017-03-27 | -$15.82M derived: sum of 2 quarters · filed 2017-03-27 | -$1.33M derived: sum of 3 quarters · filed 2017-03-27 | $8.06M derived: sum of 4 quarters · filed 2017-03-27 | ||||
| 2014-12-31 | -$994.00K 10-K · filed 2016-03-30 | $13.50M derived: sum of 2 quarters · filed 2016-03-30 | $22.89M derived: sum of 3 quarters · filed 2016-03-30 | $15.76M 10-K · filed 2016-03-30 | $21.82M 10-K · filed 2015-04-15 | |||
| 2014-09-30 | $14.49M 10-K · filed 2016-03-30 | $20.88M 10-Q/A · filed 2015-04-15 | $20.88M 10-Q/A · filed 2015-04-15 | $16.11M 10-K · filed 2016-03-30 | $22.82M 10-Q/A · filed 2015-04-15 | $12.49M derived: sum of 4 quarters · filed 2016-03-30 | ||
| 2014-06-30 | $9.39M 10-K · filed 2016-03-30 | $13.55M 10-Q/A · filed 2015-04-15 | $1.73M 10-K · filed 2016-03-30 | $1.93M 10-Q/A · filed 2015-04-15 | -$2.00M derived: sum of 3 quarters · filed 2016-03-30 | -$51.04M derived: sum of 4 quarters · filed 2016-03-30 | ||
| 2014-03-31 | -$11.62M 10-K · filed 2016-03-30 | -$18.61M 10-Q · filed 2014-05-20 | -$11.39M derived: sum of 2 quarters · filed 2016-03-30 | -$60.43M derived: sum of 3 quarters · filed 2016-03-30 | -$75.18M derived: sum of 4 quarters · filed 2016-03-30 | |||
| 2013-12-31 | $229.00K derived: 10-Q/A 12 month − 10-Q/A 9 month · filed 2015-04-15 | -$48.81M derived: sum of 2 quarters · filed 2015-04-15 | -$63.56M derived: sum of 3 quarters · filed 2015-04-15 | -$65.20M 10-Q/A · filed 2015-04-15 | -$64.33M 10-Q · filed 2014-05-20 | |||
| 2013-09-30 | -$49.04M 10-Q/A · filed 2015-04-15 | -$49.04M 10-Q/A · filed 2015-04-15 | -$65.43M 10-Q/A · filed 2015-04-15 | |||||
| 2013-06-30 | -$14.75M 10-Q/A · filed 2015-04-15 | -$16.39M 10-Q/A · filed 2015-04-15 | ||||||
| 2013-03-31 | -$1.65M 10-Q/A · filed 2015-04-15 | -$1.61M 10-Q · filed 2014-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |